戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 lyzes the conversion of reduced vitamin K to vitamin K epoxide and the concomitant conversion of glut
2 ants resulted in wild type VKOR reduction of vitamin K epoxide; however, the C43A and C51A mutants on
3 reductase complex subunit 1 (VKORC1) reduces vitamin K epoxide in the vitamin K cycle for post-transl
4 ion of the vitamin K-dependent proteins, and vitamin K epoxide is a by-product of this reaction.
5                                          The vitamin K epoxide (KO) product is recycled by two reacti
6  carboxylated reporter when fed vitamin K or vitamin K epoxide (KO).
7                                              Vitamin K epoxide (or oxido) reductase (VKOR) is the tar
8 arfarin and other 4-hydroxycoumarins inhibit vitamin K epoxide reductase (VKOR) by depleting reduced
9                                              Vitamin K epoxide reductase (VKOR) catalyzes the convers
10                                              Vitamin K epoxide reductase (VKOR) drives the vitamin K
11 oralis, and revealed the essential role of a vitamin K epoxide reductase (VKOR) gene in pilus assembl
12                                              Vitamin K epoxide reductase (VKOR) generates vitamin K h
13 isms in the cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKOR) genes have been shown
14                                              Vitamin K epoxide reductase (VKOR) is an essential enzym
15                                              Vitamin K epoxide reductase (VKOR) is essential for the
16                                        Human vitamin K epoxide reductase (VKOR) is the target of warf
17                                              Vitamin K epoxide reductase (VKOR) is the target of warf
18                                Subsequently, vitamin K epoxide reductase (VKOR) is thought to convert
19                The warfarin-sensitive enzyme vitamin K epoxide reductase (VKOR) of the cycle reduces
20 tprint membrane proteins as demonstrated for vitamin K epoxide reductase (VKOR) stabilized in a micel
21                            The intramembrane vitamin K epoxide reductase (VKOR) supports blood coagul
22                                              Vitamin K epoxide reductase (VKOR) sustains blood coagul
23   Despite its importance, warfarin's target, vitamin K epoxide reductase (VKOR), has resisted purific
24 agulation in humans requires the activity of vitamin K epoxide reductase (VKOR), the target of the an
25 K is in excess in both the untransfected and vitamin K epoxide reductase (VKOR)-transfected cells, th
26 ts quiescin-sulfhydryl oxidase 1 (QSOX1) and vitamin K epoxide reductase (VKOR).
27 hydrophilic extramembrane domains of the IMP vitamin K epoxide reductase (VKOR).
28                           Warfarin-resistant vitamin K epoxide reductase (VKOR-Y139F) supported carbo
29         Using the mammalian membrane protein vitamin K epoxide reductase (VKORc1) as a reporter, we d
30 rphisms in the cytochrome P450 (CYP) 2C9 and vitamin K epoxide reductase (VKORC1) genes.
31 d of a key pharmacologic target of warfarin, vitamin K epoxide reductase (VKORC1), contribute to diff
32 logous to the catalytic subunit of mammalian vitamin K epoxide reductase (VKORC1, EC 1.1.4.1) that is
33 n dosing is correlated with polymorphisms in vitamin K epoxide reductase complex 1 (VKORC1) and the c
34                Variants in the gene encoding vitamin K epoxide reductase complex 1 (VKORC1) may affec
35                                              Vitamin K epoxide reductase complex subunit 1 (VKORC1) r
36  on its interaction with a splice variant of vitamin K epoxide reductase complex subunit 1 (VKORC1),
37 mented but uncharacterized splice variant of vitamin K epoxide reductase complex subunit 1 (VKORC1),
38 se Inhibitor Clade G Member 1 (SERPING1) and Vitamin K epOxide Reductase Complex subunit 1 (VKORC1),
39  largely uncharacterized ER-resident protein vitamin K epoxide reductase complex subunit 1 variant 2
40 n the ER with a nonsignaling receptor called vitamin K epoxide reductase complex subunit 1 variant 2
41 ctions of vIL-6 with the ER membrane protein vitamin K epoxide reductase complex subunit 1 variant 2
42 eviously uncharacterized ER membrane protein vitamin K epoxide reductase complex subunit 1 variant 2
43 ociates with a novel membrane protein termed vitamin K epoxide reductase complex subunit 1 variant 2
44 transducer and the novel ER membrane protein vitamin K epoxide reductase complex subunit 1 variant-2
45 ide polymorphisms in cytochrome P450 2C9 and vitamin K epoxide reductase have been shown to make sign
46 ncy of single nucleotide polymorphism in the vitamin K epoxide reductase subcomponent 1 (Vkorc1) gene
47 on (Ci-Gla1, gamma-glutamyl carboxylase, and vitamin K epoxide reductase) or spatiotemporal regulatio
48 mplicate the bacterial homolog of the enzyme vitamin K epoxide reductase, a protein required for bloo
49 macromolecular interactions by inhibition of vitamin K epoxide reductase, cellular responses includin
50  orthologs of gamma-glutamyl carboxylase and vitamin K epoxide reductase.
51 oexpressing the recently identified gene for vitamin K epoxide reductase.
52                                              Vitamin-K epoxide reductase is encoded by the VKORC1 gen
53 s are widely used anticoagulants that target vitamin K epoxide reductases (VKOR), a family of integra
54        We show that in vivo VKORC1L1 reduces vitamin K epoxide to support vitamin K-dependent carboxy
55 VKOR) sustains blood coagulation by reducing vitamin K epoxide to the hydroquinone, an essential cofa
56 tif are essential for both the conversion of vitamin K epoxide to vitamin K and the conversion of vit
57 is that VKOR catalyzes both the reduction of vitamin K epoxide to vitamin K and the conversion of vit
58 eptide can accomplish both the conversion of vitamin K epoxide to vitamin K and vitamin K to reduced